Shanghai Anbaida Investment Management Consulting Co., Ltd.

Shanghai Anbaida Investment Management Consulting Co., Ltd. (Anbaida), established in 2004 (stock code: 02393), is a medical company specializing in in-vitro diagnostic products. As the exclusive agent of Roche Diagnostics in the Shanghai region within the global diagnostics field, its product sales cover 98% of hospitals at all levels in the Shanghai market, with sales revenue in the Shanghai region reaching RMB 900 million in 2015. Based on an excellent customer base and sales channels in the industry, Shanghai Anbaida obtained the agency rights for pathology products, microbiology products, and laboratory equipment of Thermo Fisher in 2013; in 2015, it secured the general agency rights for the thromboelastography products produced by Shaanxi Yu Zeyi Company in the regions of Shanghai, Jiangsu, Anhui, Jiangxi, and Zhejiang.
Anbaida serves customers including hospitals at all levels, independent laboratories, universities and colleges, research institutes, and regional testing centers, helping clients with comprehensive laboratory solutions covering complete testing equipment, laboratory equipment, testing software, after-sales service, reagents, and consumables. It also tailors various commercial cooperation models for customers to create win-win situations, while committing to the investment, construction, and operation of hospital-related departments, regional testing centers, and independent laboratories.
Leveraging over a decade of experience in providing services in the diagnostics field, Anbaida consistently upholds the service tenet of "Thinking for customers, satisfying customers." It pioneered the implementation of a customer-side electronic ordering system and a comprehensive cold-chain distribution system within the industry. With a solid software and hardware foundation, increasingly mature marketing channels, complete service and logistics systems, and clear strategic routes and internal development, Anbaida has formulated a development strategy driven by service and rooted in talent, aspiring to become a respected leader in the domestic diagnostics industry and dedicating itself to the construction of the health service industry with Chinese characteristics.